Randomized controlled trials of the renal protective effects of exerenone versus hydrochlorothiazide in hypertensive patients with CKD already on ACEI or ARB therapy.

The renal protective effects of exerenone in hypertensive patients with CKD. - The renal protective effects of exerenone in hypertensive patients with CKD.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042560

Enrollment

Registered

2020-11-26

Start date

2020-05-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

Add oral esaxerenone 1.25~2.5mg/day to the conventional therapy for 12 week Add oral hydrochlorothiazide 6.25~12.5mg/day to the conventional therapy for 12 week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients 20 years and over 2)125/75mmHg or more at home blood pressure 3)CKD stage3 4)Urine protein 0.15g/gCr or more 5)Taking ARB/ACEI

Exclusion criteria

Exclusion criteria: 1)Pations with Secondary hypertension except renal parenchymal hypertension 2)Serum potassium 5mEq/L or higher 3)Nephrotic syndrome and active nephritis 4)Taking aldosterone antagonist

Design outcomes

Primary

Measure	Time frame
Rate of change in urinary protein	—

Countries

Japan

Contacts

Public ContactShiro Komiya

Yokohama City University Medical Center Department of Nephrology and Hypertension

sh.2.komiya@gmail.com045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026